Literature DB >> 9935274

Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use?

M M Elseviers1, M E De Broe.   

Abstract

Analgesic nephropathy is a slowly progressive renal disease, characterised by renal papillary necrosis. Recently, diagnostic criteria for this disease have been defined based on renal computed tomography scanning performed without contrast. The observation of a decreased renal mass of both kidneys, combined with either bumpy contours or papillary calcifications, has been found to have high diagnostic specificity and sensitivity. However, the question remains as to what kind of analgesics can cause analgesic nephropathy. In the majority of early reports about this condition, phenacetin was singled out as the nephrotoxic culprit. However, during the last decade the nephrotoxic potential of nonphenacetin-containing preparations has become apparent. It is clear that people who abuse analgesics prefer combination analgesics containing 2 analgesics combined with caffeine and/or codeine. In contrast, abuse of products containing only aspirin (acetylsalicylic acid) or paracetamol (acetaminophen) is seldom described and associated renal disease is only occasionally reported. Experimental evidence of the nephrotoxicity of analgesic preparations is not well established. The results of studies involving analgesic administration in animals remain contradictory. Clinical evidence linking high consumption of analgesic preparations with analgesic nephropathy is overwhelming. Most patients who admit to over-consuming analgesics have taken preparation containing more than one compound. In recent years, it has become more apparent that preparations not containing phenacetin also have the potential to cause nephrotoxicity manifesting as identical renal lesions. Further epidemiological evidence of the nephrotoxic potential of analgesic combinations has come from case-control studies published during the last decade and from 2 prospective cohort studies. Effective prevention of analgesic nephropathy consists of the prohibition of over-the-counter sales of preparation containing at least 2 analgesics associated with caffeine and/or codeine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935274     DOI: 10.2165/00002018-199920010-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  44 in total

1.  Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study.

Authors:  M M Elseviers; V Bosteels; P Cambier; M De Paepe; J P Godon; R Lins; W Lornoy; E Matthys; C Moeremans; R Roose
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

2.  PHENACETIN AND RENAL DAMAGE AT A SWEDISH FACTORY.

Authors:  K GRIMLUND
Journal:  Acta Med Scand       Date:  1963

3.  Renal papillary necrosis and the abuse of phenacetin.

Authors:  L A JACOBS; J G MORRIS
Journal:  Med J Aust       Date:  1962-10-06       Impact factor: 7.738

4.  A renal lesion caused by abuse of phenacetin.

Authors:  K LARSEN; C E MOLLER
Journal:  Acta Med Scand       Date:  1959-05-20

5.  [Chronic interstitial nephritis].

Authors:  O SPUHLER; H U ZOLLINGER
Journal:  Z Klin Med       Date:  1953

6.  Paracetamol: a cause for analgesic nephropathy and end-stage renal disease.

Authors:  M Segasothy; A B Suleiman; M Puvaneswary; A Rohana
Journal:  Nephron       Date:  1988       Impact factor: 2.847

7.  Regular analgesic intake and the risk of end-stage renal failure.

Authors:  W Pommer; E Bronder; E Greiser; U Helmert; H J Jesdinsky; A Klimpel; K Borner; M Molzahn
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

8.  End-stage renal disease and non-narcotic analgesics: a case-control study.

Authors:  M Morlans; J R Laporte; X Vidal; D Cabeza; P D Stolley
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

9.  Progression of renal failure in analgesic-associated nephropathy.

Authors:  A Schwarz; U Kunzendorf; F Keller; G Offermann
Journal:  Nephron       Date:  1989       Impact factor: 2.847

10.  Analgesic use and chronic renal disease.

Authors:  D P Sandler; J C Smith; C R Weinberg; V M Buckalew; V W Dennis; W B Blythe; W P Burgess
Journal:  N Engl J Med       Date:  1989-05-11       Impact factor: 91.245

View more
  3 in total

1.  Development of a community pharmacy-based model to identify and treat OTC drug abuse/misuse: a pilot study.

Authors:  Glenda F Fleming; James C McElnay; Carmel M Hughes
Journal:  Pharm World Sci       Date:  2004-10

2.  Normal black kidney.

Authors:  Aliasghar Yarmohamadi; Ali Reza Akhavan Rezayat; Bahram Memar; Hamid Reza Rahimi; PhD Cand
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

3.  Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of Fallot.

Authors:  Ken Ohara; Tetsu Akimoto; Takuya Miki; Naoko Otani; Taro Sugase; Takahiro Masuda; Takuya Murakami; Toshimi Imai; Shin-Ichi Takeda; Yasuhiro Ando; Shigeaki Muto; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2015-11-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.